1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74–108.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49 (1): 8–31.
3. Wingo PA, Ries LA, Parker SL, Heath CW Jr. Long-term cancer patient survival in the United States. Cancer Epidemiol Biomarkers Prev 1998; 7 (4): 271–82.
4. Midgley R, Rerr D. Colorectal cancer. Lancet 1999; 353 (9150): 391–9.
5. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997; 40 (1): 15–24.
6. Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 1993; 29A (15): 2077–9.
7. Blijham GH. Chemotherapy of colorectal cancer. Anticancer Drugs 1991; 2 (3): 233–45.
8. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly lowdose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and flurouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15 (2): 808–15.
9. Mayer RJ. Chemotherapy for metastatic colorectal cancer. Cancer 1992; 70 (Suppl. 5): 1414–24.
10. Lokich JJ, Ahlgren JD, Gullo JJ et al. A prospective randomized comparison of continuous infusion fluorouracol with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989; 7 (4): 425–32.
11. Scheithauer W, Rosen H, Kornek CV et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306 (6880): 752–5.
12. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group in Cancer. J Clin Oncol 1998; 16 (1): 301–8.
13. Miwa M, Ura M, Nishida M et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentated in human liver and cancer tissue. Eur J Cancer 1998; 34 (8): 1274–81.
14. Schuller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45 (4): 291–7.
15. Sobrero A, Guglielmi A, Grossi F et al. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin Oncol 2000; 27 (5 Suppl. 10): 72–7.
16. Polle C, Gardiner J, Twelves C et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002; 49 (3): 225–34.
17. Budman DR, Meropol NJ, Reigner B et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol 1998; 16 (5): 1795–802.
18. Mackean M, Planting A, Twelves C et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998; 16 (9): 2977–85.
19. Cassidy J, Dirix L, Bissett D et al. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res 1998; 4 (11): 2755–61.
20. Van Cutsem E, Findlay M, Osterwalder B et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized Phase II study. J Clin Oncol 2000; 18 (6): 1337–45.
21. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plusleucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J Clin Oncol 2001; 19 (21): 4097–106.
22. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J Clin Oncol 2001; 19 (8): 2282–92.
23. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, Phase III trials. Br J Cancer 2004; 90 (6): 1190–7.
24. Cassidy J, Twelves C, Van Cutsem E et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compares with intravenous 5-fluorouracil/leucovorin. Ann Oncol 202; 13 (4): 566–75.
25. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18 (16): 2938–47.
26. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905–14.
27. Gil-Delgado M, Bastian G, Pauleet B et al. Final results of a pharmacokinetic (PK) study of capecitabine (X) in combination with oxaliplatin (O) for patients (pts) with metastatic colorectal cancer (MCRC). Am Soc Clin Oncol 2005; 23 (16 Suppl. 1): Abstr 3685.
28. Diaz-Rubio E, Evans TR, Tabemero J. Capecitabine (Xeloda) in combination with oxaliplatin: a Phase I, dose-escalation study in patients with advaced or metastatic solid tumors. Ann Oncol 2002; 13: 558–65.
29. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin), active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22 (11): 2084–91.
30. Sumpter K, Harper-Wynne C, Cunningham D et al. Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institutions's experience. Clin Oncol (R Coll Radiol) 2003; 15 (5): 221–6.
31. Makatsoris T, Kalofonos HP, Aravantinos G et al. A Phase II study of capecitabine plus oxaliplatin (XELOX), a new first-line option in metastatic colorectal cancer. Int J HGastrointest Cancer 2005; 35 (2): 103–9.
32. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter Phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21 (7): 1307–12.
33. Cassidy J, Clarke S, Rubio E et al. XELOX vs. FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized Phase III trial in first-line metastatic colorectal cancer (MCRC). Am Soc Clin Oncol Gastrointestinal Cancers Symposium. Orlando, FL, USA, 19-21 January 2007; Abs. 270.
34. Hochster HS. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectla cancer. Semin Oncol 2006; 33 (5 Suppl. 10): S8–14.
35. Rea DW, Nortier JW, Ten Bokkel Huinink WW et al. A Phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Ann Oncol 2005; 16 (7): 1123–32.
36. Nishimura G. Evidence of increased effect of thymidine phosphorylase by irinotecan: a proof for the intensified efficacy by combination with irinotecan and capecitabine. Am Soc Clin Oncol Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 26–28 January 2006; Abstr. 298.
37. Patt Y. Final efficacy and safety findings from a Phase II trial of capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC). eur Soc Med Oncol Congress 2004; Abstr. 286.
38. Bajetta E, Di Bartolomeo M, Mariani L et al. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 2004; 100 (2): 279–87.
39. Gold P. Capecitabine and irinotecan as 1st line therapy for patients with metastatic colorectal cancer: Phase II study preliminary results. Am Soc Clin Oncol 2003; Abs. 1158.
40. Munoz A, Salud A, Ciron C et al. Randomised Phase III trial comparing irinotercan plus capecitabine (XELIRI regimen) vs. irinotecan, 5-FU and folinic acid (Saltz regimen) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC). Ann Oncol 2006; 17 (Suppl. 9): Abs. 345P.
41. Fuchs CS, Marshall J, Mitchell EP et al. A randomised trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). Am Soc Clin Oncol 2006; Abs. 3506.
42. Kohne C, de Greve C, Bokemeyer I et al. Capecitabine plus irinotecan versus 5-FU/FA/irinotecan +/- celecoxib in the first line treatment of metastatic colorectal cancer. Safety results of the prospective multicenter EORTC Phase III study 40015. Am Soc Clin Oncol 2005; Abs. 3525.
43. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Poooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345 (8955): 939–44.
44. O'Connell MJ, Mailliard JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15 (1): 246–50.
45. Moertel CG, Fleming TR, Macdonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122 (5): 321–6.
46. Scheithauer W, McKendrick J, Begbie S et al. Oral capecitabine as an alternative to i.v. 5-fluorouracol-based adjuvant therapy for colon cancer: safety results of a randomized, Phase III trial. Ann Oncol 2003; 14 (12): 1735–43.
47. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352 (26): 2696–704.
48. Schmoll HJ, Cartwright T, Tabernero J et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007; 25 (1): 102–9.
49. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intraventous palliative chemotherapy. J Clin Oncol 1997; 15 (1): 110–5.
50. Twelves C, Boyer M, Findlay M. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil ;lus leucovorin in a Phase III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer 2001; 37 (5): 597–604.
51. Cassidy J, Douillard JY, Twelves C et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes'C colon cancer: the X-ACT trial. Br J Cancer 2006; 94 (8): 1122–9.

________________________________________________

C.Kelly, J.Cassidy